Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness

PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is largely considered a nonimmunogenic malignancy; however, approximately 1%, of patients may have tumors with deficient mismatch repair, high microsatellite instability, or high tumor mutational burden (TMB ≥10 mutations/Mb), which may be predictive...

Descripción completa

Detalles Bibliográficos
Autores principales: Quintanilha, Julia C.F., Storandt, Michael H., Graf, Ryon P., Li, Gerald, Keller, Rachel, Lin, Douglas I., Ross, Jeffrey S., Huang, Richard S.P., Schrock, Alexa B., Oxnard, Geoffrey R., Chakrabarti, Sakti, Mahipal, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581638/
https://www.ncbi.nlm.nih.gov/pubmed/37410975
http://dx.doi.org/10.1200/PO.23.00092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581638/
https://www.ncbi.nlm.nih.gov/pubmed/37410975
http://dx.doi.org/10.1200/PO.23.00092

Ejemplares similares